Mr. Thomas Smeenk reports

HEMOSTEMIX CLOSES $480,000 PRIVATE PLACEMENT AT $0.12 PER SHARE

Hemostemix Inc. has closed a non-brokered private placement for aggregate gross proceeds of $480,000, through the issuance of four million common shares of the company at a price of 12 cents per common share.

The proceeds from the private placement will be used for general working capital purposes, including advancing the company's regulatory, clinical and commercialization initiatives related to ACP-01 (VesCell), Hemostemix's autologous angiogenic cell therapy platform.

All securities issued pursuant to the private placement are subject to a statutory hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The private placement remains subject to final acceptance by the TSX-V.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed and patented, and is scaling and selling, autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.